Patent References
4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections Patent #: 5041449
2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties Patent #: 5047407
Method and compositions for the synthesis of BCH-189 and related compounds Patent #: 5204466
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds Patent #: 5210085
Antiviral nucleoside combination Patent #: 5234913
Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof Patent #: 5461060
Processes for preparing substituted 1,3-oxathiolanes with antiviral properties Patent #: 5466806
1,3-oxathiolanes useful in the treatment of hepatitis Patent #: 5486520
Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B Patent #: 5532246
1,3-oxathiolane nucleoside compounds and compositions Patent #: 5538975
More ...
Synergistic antiviral compositions Patent #: 5604209
1,3-oxathiolane nucleoside analogues and methods for using same Patent #: 5618820
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds Patent #: 5700937
Method of resolution of 1,3-oxathiolane nucleoside enantiomers Patent #: 5728575
Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers Patent #: 5892025
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds Patent #: 5814639
Method of resolution of 1,3-oxathiolane nucleoside enantiomers Patent #: 5827727
Inventors
Assignee
Application No. 056548 filed on 04/07/1998
US Classes: 514/274 ,
Chalcogen bonded directly to pyrimidine at 2-position 514/253.01 ,
The additional hetero ring is six-membered consisting of one nitrogen and five carbon atoms 514/263.4 Nitrogen bonded directly to ring carbon of the purine ring system (e.g., adenine, etc.)
Examiners Primary:
Travers, Russell
Attorney, Agent or Firm
Foreign Patent References 0382526 EP. 08/13/1990 0515144 EP. 11/13/1992 0515156 EP. 11/13/1992 0515157 EP. 11/13/1992 0526253 EP. 02/13/1993 55-87777 JP. 07/13/1980 WO 91/11186 WO. 08/13/1991 WO 92/14743 WO. 09/13/1992 WO 94/14802 WO. 07/13/1994 WO 97/21706 WO. 06/13/1997
International Classes A01N 043/54
A01N 043/90
Abstract Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.
Other References Abobo et al., Journal of Pharmaceutical Sciences, 83(1):96-99 (1994) Baker et al., Journal of Medicinal Chemistry, 10(3):304-311 (1967) Balzarini et al., Antimicrobial Agents and Chemotherapy, 39(4):998-1002 (1995) Balzarini et al., Molecular Pharmacology, 49:882-890 (1996) Benhida et al., Tetrahedron Letters, 37(7):1031-1034 (1996) Brennan et al., Antiviral Research, 26:173-187 (1995) Chemical Abstracts, 107:129717w (1987) Chu et al., Journal of Medicinal Chemistry, 32: 612 (1989) Drabikowska et al., 42(3):288-296 (1987) Furman et al., Antimicrobial Agents and Chemotherapy, 36(12):2686-2692 (1992) Hoong et al., Journal of Organic Chemistry, 57:5563-5565 (1992) Jablonowski et al., AIDS Forshung (AIFO), 563-568 (1994) Kilby, J. Michael and Michael S. Saag, Infectious Agents and Disease, 3(6):313-323 Okamoto et al., Antiviral Research, 31:69-77 (1996) Schinazi, r.F. et al., Antimicrobial Agents and Chemotherapy, 36(11):2432-2438 Seki et al., Antiviral Chemistry & Chemotherapy, 6(2):73-79 (1995) Smerdon et al., Proc. National Academy of Science USA, 91:3911-3915 (1994) Wilson et al., Antimicrobial Agents and Chemotherapy, 37(8):1720-1722 (1993) Yuasa et al., Molecular Pharmacology, 44:895-900 (1993
April 7, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
